Dados B3 › TELB4 × VIVT3 · Português
Each row uses the most recent year in which BOTH companies have the figure, and says which year that is. A cell with ! carries a caveat — hover to read it. We do not name a winner: that would be a recommendation, and this site does not give any.
| indicator | TELB4 | VIVT3 | year |
|---|---|---|---|
| ROE | 8.7%! | 8.9% | 2025 |
| ROIC | 67.4% | 10.1% | 2025 |
| ROA | 3.3% | 4.9% | 2025 |
| Gross margin | -35.0% | 44.8% | 2025 |
| EBIT margin | 48.2% | 16.5% | 2025 |
| Net margin | 28.6% | 10.4% | 2025 |
| Net debt/EBITDA | -2.94x | 0.53x | 2025 |
| Current ratio | 6.29x | 1.00x | 2025 |
| Revenue growth (1y) | 18.5% | 6.7% | 2025 |
| Revenue growth (5y CAGR) | 13.0% | 6.7% | 2025 |
| Piotroski F-Score | 6/9 | 7/9 | 2025 |
Priced at the first session on or after the day each filing became public — never the period close.
| indicator | TELB4 | VIVT3 | year |
|---|---|---|---|
| P/E | 6.53x | 21.78x | 2025 |
| P/B | 0.52x | 1.95x | 2025 |
| EV/EBITDA | -1.14x | 5.95x | 2025 |
| FCF yield | 2.9% | 8.4% | 2025 |
Numbers on this page are live. Data version 2026-09-01-supressao-declarada · page generated 2026-09-08 14:12 UTC. If this does not match /saude, you are reading a cached copy.
Home · Methodology · Transparency · Audit it